$63.34—
NYSE
$63.34—
Novartis and Bristol Myers Squibb have halted several CAR-T trials in autoimmune diseases due to immune-related adverse events. Side effects observed in testing have led Novartis to halt development.
Bristol Myers Squibb has received FDA approval for Zenbexus, a treatment for advanced multiple myeloma. This marks the debut of a new class of drugs known as CELMoDs for the blood cancer.
The U.S. FDA has granted accelerated approval to Bristol Myers Squibb's first CELMoD therapy, ZENBEXUS™, in combination with Daratumumab and Hyaluronidase for patients with multiple myeloma as early as first relapse.
Bristol Myers Squibb has received FDA approval for Zenbexus, a treatment for advanced multiple myeloma. This marks the debut of a new class of drugs known as CELMoDs, which are designed to target and degrade specific proteins involved in the disease.
The U.S. FDA has granted accelerated approval to Bristol Myers Squibb's first CELMoD therapy, ZENBEXUS™, in combination with Daratumumab and Hyaluronidase for patients with multiple myeloma. This marks a significant milestone as it is the first approval for a new class of protein-degrading drugs targeting this blood cancer.
The U.S. FDA has granted accelerated approval to Bristol Myers Squibb's first CELMoD therapy, ZENBEXUS™, in combination with Daratumumab and Hyaluronidase for patients with multiple myeloma. This approval marks a significant milestone as it is the first for a new class of protein-degrading drugs aimed at treating this advanced blood cancer.
The U.S. FDA has granted accelerated approval to Bristol Myers Squibb's first CELMoD therapy, ZENBEXUS™, in combination with Daratumumab and Hyaluronidase for patients with multiple myeloma. This marks a significant milestone as it is the first approval for a new class of protein-degrading drugs aimed at treating this advanced blood cancer.
The U.S. FDA has granted accelerated approval to Bristol Myers Squibb's first CELMoD therapy, ZENBEXUS™, in combination with Daratumumab and Hyaluronidase for patients with multiple myeloma. This marks a significant milestone as it is the first approval for a new class of protein-degrading drugs aimed at treating this advanced blood cancer.
The FDA approved a treatment for advanced multiple myeloma made by Bristol Myers Squibb, marking the debut of a new class of drugs for the blood cancer.
The FDA approved a treatment for advanced multiple myeloma made by Bristol Myers Squibb, marking the debut of a new class of drugs for the blood cancer.
The FDA approved a treatment for advanced multiple myeloma made by Bristol Myers Squibb, marking the debut of a new class of drugs for the blood cancer.
The FDA approved a treatment for advanced multiple myeloma made by Bristol Myers Squibb, marking the debut of a new class of drugs for the blood cancer.
Bristol Myers' blood cancer cell therapy meets main goal in mid-stage trial
Drugmakers quietly halted autoimmune drug trials because of deaths or problematic side effects, raising questions about disclosure around experimental research
Revisiting Stock Picks Dexcom, Bristol Myers Squibb, Quanta Services
Bristol Myers ends blood cancer drug deal with cell therapy maker Cellares
US FDA approves Bristol Myers' blood cancer treatment